KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Change in Inventory (2016 - 2025)

Neogenomics' Change in Inventory history spans 16 years, with the latest figure at $28000.0 for Q4 2025.

  • For Q4 2025, Change in Inventory fell 98.78% year-over-year to $28000.0; the TTM value through Dec 2025 reached $1.5 million, down 42.83%, while the annual FY2025 figure was $1.5 million, 42.83% down from the prior year.
  • Change in Inventory reached $28000.0 in Q4 2025 per NEO's latest filing, up from -$5.6 million in the prior quarter.
  • In the past five years, Change in Inventory ranged from a high of $4.1 million in Q2 2025 to a low of -$5.6 million in Q3 2025.
  • Average Change in Inventory over 5 years is $208100.0, with a median of $447000.0 recorded in 2021.
  • The largest YoY upside for Change in Inventory was 1034.16% in 2024 against a maximum downside of 2018.0% in 2024.
  • A 5-year view of Change in Inventory shows it stood at $1.6 million in 2021, then crashed by 55.38% to $697000.0 in 2022, then plummeted by 71.02% to $202000.0 in 2023, then surged by 1034.16% to $2.3 million in 2024, then crashed by 98.78% to $28000.0 in 2025.
  • Per Business Quant, the three most recent readings for NEO's Change in Inventory are $28000.0 (Q4 2025), -$5.6 million (Q3 2025), and $4.1 million (Q2 2025).